Liu Cheng's Form 4 filing
Estrella Immunopharma, Inc. (ESLA) · filed Aug 26, 2026
- Accession no.
- 0001996255-26-000004
- Filed
- Aug 26, 2026, 7:23 PM ET
- Trade date
- Aug 25, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Liu ChengCIK 0001996255 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +100,000 | $0.815F1 | +$81,500 | 397,437 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock | MOption exerciseAcquired | +100,000 | $0.00F4 | $0 | 900,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
Referenced by the price of 1 transaction in Table I.
- F4
Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.
Referenced by the price of 1 transaction in Table II.